Declaration of Boles

Exhibit A

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF TENNESSEE

PLANNED PAKEN I HOOD OF)
TENNESSEE AND NORTH)
MISSISSIPPI, MEMPHIS CENTER FOR)
REPRODUCTIVE HEALTH,)
KNOXVILLE CENTER FOR)
REPRODUCTIVE HEALTH,)
FEMHEALTH USA, INC., d/b/a)
CARAFEM, and AUDREY LANCE,)
)
Plaintiffs,)
v.) Case No. 3:20-cv-00740
	Judge Campbell
HERBERT H. SLATERY III, Attorney	
General of Tennessee, in his official	
capacity; LISA PIERCEY, M.D.,)
Commissioner of the Tennessee)
Department of Health, in her official)
capacity; RENE SAUNDERS,)
M.D., Chair of the Board for Licensing)
Health Care Facilities, in her official)
capacity; W. REEVES JOHNSON, JR.,)
M.D., President of the Tennessee Board)
of Medical Examiners, in his official)
capacity; HONORABLE AMY P.)
WEIRICH, District Attorney General)
of Shelby County, Tennessee, in her)
official capacity; GLENN FUNK, District)
Attorney General of Davidson County,)
Tennessee, in his official capacity;)
CHARME P. ALLEN, District Attorney)
General of Knox County, Tennessee, in her)
official capacity; and TOM P.)
THOMPSON, JR., District Attorney)
General for Wilson County, Tennessee, in)
his official capacity,)
)
Defendants.)

DECLARATION OF DR. BRENT BOLES

- I, Brent Boles, M.D., pursuant to the provisions of 28 U.S.C. § 1746, do hereby declare as follows:
 - 1. I am Brent Boles, a practicing obstetrician and gynecologist in Murfreesboro, Tennessee.
 - 2. I have been board certified for more than twenty years and have been in practice in Murfreesboro for the last fifteen years. I teach at the University of Tennessee School of Medicine and the Meharry College of Medicine. I also am a member of the Medical Advisory Board for both Heartbeat International and Abortion Pill Reversal (or Rescue). ("APR"). I have attached my curriculum vitae as *Exhibit 1*.
 - 3. On March 10, 2020, I testified before the Tennessee General Assembly, specifically the House Health Committee, on HB 2568 (the provisions of which were subsequently enacted as part of HB2263/SB2196). At that hearing, an amendment was offered to the bill that would require abortion providers to inform a patient seeking a medication abortion that, if the patient changes her mind after taking the first pill, she may be able to avoid, cease, or reverse the effects of that first pill in the two step abortion pill series, particularly if she seeks assistance fast enough. I testified about the need to provide women with this information that there is a medical regime that is both safe and potentially effective in reversing the effect of the first pill. Attached as *Exhibit 2* is a true and correct transcription by a court reporter of my testimony as part of this bill's Legislative History. (*See* Ex. 2, p. 4, l. 16—p. 45, l. 25).
 - 4. The abortion pill medication treatment involves two pills: Mifeprex or mifeprestone or RU486 (it goes by three different terms), and Cytotec or misoprostol. (*See generally* Ex. 2, p. 5, l. 10—p. 6, l. 1).

- 5. The first pill, mifepristone, is a progesterone blocker. Progesterone is a hormone that is vital to the success of a pregnancy throughout the course of a pregnancy. When the action of progesterone is interfered with in the first trimester by Mifepristone, the drug may cause loss of the embryo or the fetal life, and in some cases expulsion of the pregnancy tissue.
- 6. Mifepristone alone is not always effective in ending a pregnancy. A study of data published by Dr. Daniel Grossman (an abortion provider) found that as few as 8% of pregnancies survived when only mifepristone was administered. (*See* Ex. 2, p. 22, l. 19—p. 23, l. 13).
- 7. The second pill, Cytotec, ensures that the tissue is expelled and is given twenty-four to forty-eight hours after the first pill.
- 8. When a patient has changed her mind and has taken the mifepristone but has not yet taken the Cytotec, administering natural progesterone may result in preventing loss of the fetal life in as many as sixty-eight percent (68%) of pregnancies. (*See* Ex. 2, p. 5, l. 10—p. 6, l. 13). The administration of natural progesterone has not been shown to have any increase in birth defects or in adverse effects for women and is safer that taking the mifepristone and simply choosing to not take the Cytotec. (*See generally* Ex. 2, p. 6, l. 14—p. 7, l. 19).
- 9. As part of the Abortion Pill Reversal network, I am on call to help advise and assist mothers who take the first abortion pill, change their mind, want to try to save their baby, and find the network (typically through their own searching). (*See generally* Ex. 2, p. 27, 1. 4—p. 28, 1. 5).
- 10. I do not keep a list, but I would estimate that I have prescribed natural progesterone to more than 20 women who wanted to reverse their abortion processes some right here in Tennessee who then had healthy babies. The Abortion Pill Reversal network has tracked more than 1,000 living, healthy babies with no increased risk of birth defects who have

p. 15, l. 10; p. 44, l. 14—p. 45, l. 17).

- 11. I have even delivered some of those babies myself and have seen firsthand how the abortion pill process can be reversed in some situations.
- 12. Published studies, such as in 2007, 2012, and 2018, support the efficacy of this progesterone treatment. (See Ex. 2, p. 7, 1. 6-19; p. 22, 1. 19—p. 23, 1. 13; p. 30, 1. 15—p. 31, 1. 22). The largest case study in 2018 included 754 patients. Those who took the currently recommended progesterone regimen had a 68% success rate in reversing the abortion process—with no increased outcomes that were unfavorable for the mother or for the baby.
- 13. This method of progesterone treatment has not been shown to cause any increase in adverse effects for the women who choose to pursue the treatment.
- 14. Further, this method of progesterone treatment has not been shown to cause any increase in birth defects for the fetuses of the women who choose to pursue the treatment.
- 15. A study released by the American College of Obstetrics and Gynecology, which was authored by Dr. Creinin (an abortion physician), unsuccessfully attempts to support a claim, based upon only a series of 12 patients, that attempting to reverse the abortion process is neither safe nor effective. Analysis of the three patients who experienced bleeding issues (out of the twelve total patients) showed that two of those who took mifepristone and a placebo needed hospital treatment, while the one who received progesterone treatment, upon arriving at the hospital, was found to not need surgical

/

¹ See Delgado G, Davenport M. Progesterone use to reverse the effects of mifepristone. Annals of Pharmacotherapy. 46 2012 Dec;46(12):e36.; Delgado G, et al. A case Series Detailing the Successful Reversal of the Effects of Mifepristone Using Progesterone. Issues in Law and Medicine (2018) 33(1): 21-31.

intervention or a blood transfusion for the deceased embryo she spontaneously passed. (See Ex. 2, p. 8, l. 1—p. 10, l. 2; p. 11, l. 3—p. 13, l. 12; p. 15, l.23—p. 17, l. 10; p.42, l.2—22).

- 16. The American Medical Association's Code of Ethics in sections 1.1.1 and 1.1.3 require the physician treating the patient to give an accurate and complete disclosure of information in the informed consent process and to do so in a manner that it is not self-serving to the physician's own interests. (See Ex. 2, p. 10, l. 1-12).
- 17. With a success rate that may be as high as 68%, women need to be told of the possibility that progesterone treatment may assist in reversing their abortion process after taking the mifepristone if they so choose. To not inform them of this possibility is to not give them a full and complete disclosure in the informed consent process (and particularly if the women inquires after taking the first pill) and is a violation of both sections of the AMA's Code of Ethics. (See Ex. 2, p. 23, l. 14—23).
- 18. Tennessee's recently passed abortion law (HB2263/SB2196) is an important step in ensuring that mothers receive complete and accurate information that the abortion process "may be possible to avoid, cease, or even reverse the intended effects of a chemical abortion utilizing mifepristone" (emphasis added).

I declare under penalty of perjury that the foregoing is true and correct. Executed by me on the th day of September, 2020, in Murfreesboro, Tennessee.

C. BRENT BOLES, M.D. 9/14/2020

Curriculum Vitae of Boles

Attachment 1

C. Brent Boles, M.D. Covenant Healthcare for Women, P.L.L.C.

1800 Medical Center Parkway Suite 325 Murfreesboro, Tennessee 37129 615-867-0034

Professional History

- Physician and Owner, Covenant Healthcare for Women, P.L.L.C., January, 2006 to present
- Medical Director of Portico (local crisis pregnancy center) 2008 to present
- Vice Chief of Obstetrics and Gynecology, Middle Tennessee Medical Center, Murfreesboro TN, 2007-2008
- Chief of Obstetrics and Gynecology, Middle Tennessee Medical Center, Murfreesboro TN, 2009-2010
- Associate Clinical Professor in the University of Tennessee Department of Emergency Medicine at Saint Thomas Rutherford Hospital, July 2015 to present
- Associate Clinical Professor and Assistant Residency Director for the Saint Thomas Rutherford Campus, Department of Obstetrics and Gynecology, Meharry College of Medicine, 2006 to present
- Clinical Instructor for the University of Tennessee Physician Assistant School, 2016 to present
- IC Research, Principal Investigator, 2018 to present
- OB/GYN Associates, July 2005-December 2005
- Murray Woman's Clinic, July 1996-June 2005
- Middle Tennessee Medical Center Laborist Program Director, November 2006-March 2011
- Certified on the Da Vinci Xi robotic surgery platform
- Member of the Medical Advisory Board for Heartbeat International
- Member of the Medical Advisory Board for Abortion Pill Reversal

Educational History

- Certified by the American Board of Obstetrics and Gynecology, November 1998 to present
- Chief Administrative Resident, University of Louisville School of Medicine, Department of Obstetrics and Gynecology, July 1995 June 1996
- Internship and Residency, University of Louisville School of Medicine, Department of Obstetrics and Gynecology, July 1992-June 1996
- Doctor of Medicine, University of Louisville School of Medicine, August 1988-May 1992
- Bachelor of Science in Biology, Murray State University, August 1984-May 1988

Licensure

- Tennessee Board of Medical Examiners, 2004 to present
- Kentucky Board of Medical Licensure, 1993 to 2011
- Drug Enforcement Agency Registration, 1993 to present

Memberships

- American Institute of Ultrasound in Medicine, 1998 to 2005
- International Society for Clinical Densitometry, 1998 to 2005
- Christian Medical and Dental Association
- American Association of Pro-Life Obstetricians and Gynecologists

Awards

- Professor of the Year Award, University of Tennessee Health Science Center, Saint Thomas Rutherford Department of Emergency Medicine, 2016
- Meharry Appreciation Award, 2009
- Foundation Award for Clinical Excellence, Department of Obstetrics and Gynecology, University of Louisville School of Medicine, 1994
- Best Clinical Teacher Awards, University of Louisville School of Medicine, 1993, 1994, 1996

- Clinical Research Awards, University of Louisville School of Medicine, Department of Obstetrics and Gynecology, 1995 and 1996
- Laparoscopic Skills Award, University of Louisville School of Medicine, Department of Obstetrics and Gynecology, 1995
- Presidential Scholarship Award, Murray State University, 1984 to 1988

House Health Committee HB2568

Attachment 2

LEGISLATIVE HISTORY - HOUSE HEALTH COMMITTEE (HB2568)

AUDIO RECORDING March 10, 2020



VETERAN COURT REPORTING D. Rochelle Koenes, RPR, LCR veterancourtreporting@gmail.com (931) 919-8932

1	LEGISLATIVE	HISTORY-HOUSE	HEALTH	COMMITTEE	(HB2568)
2					
3					
4					
5					
6					
7					
8					
9					
LO					
L1					
12		AUDIO F	RECORDII	NG	
13		of			
14	HOUSE BILL 2568 dated				
L5					
16		March	10, 202	20	
17					
18					
L9					
20					
21					
22		Veteran Cou			
23	`	veterancourtrer D. Rochelle Ko	enes, I	RPR, LCR	
24		Clarksville,		see 37043	
25		(931)9	19-8932	2	

1 Ν 2 E Ε D I 3 (WHEREUPON, the following is 4 transcribed from an audio recording as follows:) 5 IN THE HOUSE HEALTH COMMITTEE 6 March 10, 2020 7 (WHEREUPON, On the above date, there 8 9 came up for consideration in the House Health 10 Committee of the Tennessee House, House Bill 2568, 11 sponsored by Representative Faison, and discussion 12 pertaining to this bill was as follows:) 13 14 MR. CHAIRMAN: And with that we have a 15 pretty extensive calendar today, and I would like to 16 get us to Item Number 1, House Bill 2568 by --17 Representative Faison you are recognized. 18 REPRESENTATIVE FAISON: Good morning, 19 Committee, Mr. Chairman. 2.0 MR. CHAIRMAN: Do you have a motion? 2.1 UNIDENTIFIED SPEAKER: Second. 22 REPRESENTATIVE FAISON: Committee, House 23 Bill 2568 is a bill that I brought in the attempt 24 for if a young lady has decided to go get an 25 abortion, and it's the abortion where they give a

1 pill -- they typically give two pills -- one you 2 take at the clinic and one 48 hours later that you If they have -- for whatever reason, they 3 change their mind, I want them to know that there's 4 5 a possibility that they can get that reversed and this bill would have an -- abortion clinic providers 6 7 put up a posting that there is a possibility that you can reverse it and also let them know if they 8 9 change their mind that they can reverse it. 10 MR. CHAIRMAN: You have an amendment on 11 the bill? 12 REPRESENTATIVE FAISON: I do, yes, sir. 13 And the Amendment Drafting Code is 0148 -- -14982. 14 MR. CHAIRMAN: Drafting Code 014982. 15 have a motion and a second. 16 The amendment is properly before Okay. 17 us. Can you give us comments on the amendment? 18 REPRESENTATIVE FAISON: Just exactly what I just said. 19 2.0 MR. CHAIRMAN: Do we have questions from 2.1 the committee on the amendment? If not, we do have 22 somebody -- we were supposed to have two people here 2.3 to testify on this -- on the amendment. We can 2.4 either take questions now or we can go out of 25 session.

1 I think only one person has shown up to 2 testify. But do we have any questions before we go out of session? 3 4 Representative Clemmons, do you have a 5 question? 6 REPRESENTATIVE CLEMMONS: I was just 7 going to recommend that we go out of session first and then defer questions until after that. 8 9 MR. CHAIRMAN: All right. Seeing none, 10 without objection, we will go out of session. 11 Our first -- I believe, maybe, the only 12 person that we have here that may testify, 13 Dr. Brent Boles, if you can come up and please make 14 sure the mic is on. Tell us who you are and who 15 you're with. 16 DR. BOLES: Good morning. My name is 17 Brent Boles. I am an OB/GYN who's been board 18 certified for more than 20 years and has been in 19 practice in Murfreesboro for the last 15 years. In 2.0 addition to my private practice and academic 2.1 teaching appointments that I have with both the 22 University of Tennessee School of Medicine and the 23 Meharry College of Medicine, I am a member of the 2.4 medical advisory board for both Heartbeat 25 International and Abortion Pill Reversal.

I'm here this morning to speak in support of the representative's bill that would require abortion providers to simply notify a patient during the informed consent process that if they choose to change their mind after they have taken the first pill, that there is a medical regimen that is both safe and effective that has the potential to reverse the effects of the first pill in the abortion pill series.

2.0

2.1

2.3

2.4

The history of abortion pill medication treatment is that in the year 2000 the Food and Drug Administration approved a drug produced by a pharmaceutical company called Danco. That drug is known as Mifeprex for mifepristone or RU486. There are three different terms by which it is called.

This pill is a progesterone blocker.

Progesterone is a hormone that is vital to the success of a pregnancy throughout the course of the pregnancy. And when the action of progesterone is interfered with in the first trimester, the mifepristone will cause loss of the embryo or the fetal life. And then in some cases, cause expulsion of the pregnancy tissue. In order to ensure that the tissue is expelled, a second medication called Cytotec is given 24 to 48 hours

after the first pill is dosed.

2.0

2.1

2.4

Basic principals of pharmacology have led us to discover that when a patient has changed her mind and has taken the mifepristone but has not yet taken the Cytotec, that if you simply administer natural progesterone, you have as high as a 68 percent success rate in preventing loss of the fetal life.

This method of treatment has not been shown to cause any increase in adverse effects for the women who choose to pursue this. In fact, it is more safe than taking the mifepristone and simply not using the Cytotec.

This was discovered first in 2007 by a physician named Matthew Harrison in South Carolina who was approached by a patient who had taken the mifepristone and desired to change her mind. He studied the pharmacology of the drug and gave her a prescription of progesterone and she later delivered a living baby at term. At the same time, Dr. George Delgado on the west coast was approached with a similar problem by a similar patient and found similar results.

The first case series that was published that reported on this was released in

2012. It was a small case series and that is the criticism that the abortion industry has of this process. They claim that such a small case series with only six patients cannot be used to draw any conclusions.

2.0

2.1

2.3

2.4

The truth of the matter is that case series showed a two out of three success rate of the six patients who pursued reversal. Four delivered living babies later in their pregnancy. That is not the only study, but the abortion industry would like for you to believe that it was. There have since been at least three other published studies, the largest one of which included 754 patients in whom the current recommended regimen had a 68 percent success rate at reversing the abortion process with no increased outcomes that were unfavorable for the mother or the baby. There were no birth defects. There were no other issues reported in that study.

Another study is about to begin, and I will be one of the principal investigators in this study that will compare methods of administering the progesterone. So there's ongoing research that I believe will continue to demonstrate both the efficacy and the safety of this medication.

The recent study that was released by the American College of Obstetrics and Gynecology authored by Dr. Creinin, who is an abortion physician, makes the claim, based on a series of only 12 patients, that attempting to reverse abortion is neither safe nor effective.

2.0

2.1

2.4

I find it interesting that the abortion industry's criticism of the Delgado case series in 2012 focused on the fact that it only had a small number of patients and you can't draw conclusions from that, but now they expect us to draw conclusions from a study that also has a small number of patients, namely only 12. They claim from this study that it is -- that you -- it is not safe for the patient to take the mifepristone and then not complete the process with the Cytotec.

They make this conclusion because three of the twelve patients in that study had to go to the emergency room for bleeding. The truth of the matter when you break down those numbers, there were six patients in the study who took mifepristone and placebo, meaning they were not being treated for attempted reversal, the other six patients took mifepristone and progesterone in the current recommended regimen.

Of the six patients who took progesterone, five of them had ongoing pregnancies. So the success rate was five out of six, more than 80 percent. One of those patients was taken to the emergency room because she was worried about the amount of bleeding that she had. But when she arrived at the emergency, her embryo was no longer living and she spontaneously passed the tissue without requiring a DNC or any other surgical intervention and without requiring a blood transfusion. The other two patients who required treatment in the emergency room, both were taken to the emergency room because of heavy bleeding. Both required surgical aspiration of the pregnancy tissue, and one of the two required a transfusion.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

2.1

22

23

2.4

25

So the real conclusion that you can draw from the Creinin study is that it is not safe to take mifepristone and then decide not to take the Cytotec. So when a patient changes her mind, if she can't get help and can't figure out how to reverse the process and decides not to take the Cytotec, then that is dangerous for her. But the other conclusion is that when she takes the -- when she is made aware of the reversal regimen and takes it, it is not only safe but it is effective at a

1 minimum 68 percent of the time and perhaps as much 2 as more than 80 percent of the time. The American Medical Associations Code 3 of Ethics in sections 1.1.1 and 1.1.3 require the 4 5 physician treating the patient to give a full, accurate, and complete disclosure of information in 6 7 the informed consent process and do so in a way that is not self-serving the patient's own 8 9 interest -- or the physician's own interest. Refusing to tell patients that a reversal regimen 10 is possible is a violation of both sections of the 11 12 AMA code of ethics. 13 MR. CHAIRMAN: Thank you for that 14 testimony. 15 Do we have questions while we are --16 Representative Dixie, you are 17 recognized. 18 REPRESENTATIVE DIXIE: Thank you, 19 Mr. Chairman. I just have a couple of quick 2.0 questions. 21 You gave us a lot of stats about 22 Obviously, most studies say that they are studies. 23 extensive and hundreds, if not thousands of 2.4 patients. 25 Why was this study stopped at six

1 patients? 2 DR. BOLES: Which study? 3 REPRESENTATIVE DIXIE: Well, you said 4 earlier that there was a study that had six patients 5 that went through and they took both and then the 6 other one had the placebos. Why was it only stopped 7 at twelve people? DR. BOLES: You're referring to the 8 9 Creinin study, which had six patients in each arm. There were twelve patients in the study. 10 11 initial plan was to enroll 40. It is typical when 12 you're conducting a study and you see what you 13 believe are adverse outcomes to stop the study early 14 if there are indications that it is dangerous to the 15 patient. The stated reason for stopping the study 16 was that three patients had to -- three out of 17 twelve had to be taken to the emergency room for 18 bleeding. 19 REPRESENTATIVE DIXIE: Really, three out 2.0 of six because six only had placebos. 21 DR. BOLES: There were twelve patients 22 One of the patients who went to the ER for total. 2.3 bleeding came from the progesterone group and two of 2.4 them came from the placebo group. So the study at 25 that point had twelve patients enrolled with a plan

1 to enroll 40. But they stopped because three of the 2 twelve were evaluated for bleeding. REPRESENTATIVE DIXIE: I want to circle 3 4 back to make sure I got your answer correct. 5 DR. BOLES: Okay. REPRESENTATIVE DIXIE: You said that it 6 7 was stopped because they thought it would have adverse effects going forward. 8 9 DR. BOLES: Yes. They stopped the study 10 because three of the twelve patients had to be 11 evaluated for bleeding. When you evaluate which 12 patients had to be evaluated for bleeding, only one 13 was from the progesterone group. And she did not 14 need a blood transfusion and she did not need 15 surgery. The patients who had to have 16 interventions -- surgery and/or a blood 17 transfusion -- came from the group that took the 18 Mifeprex but did not take the progesterone to 19 attempt to reverse. 2.0 REPRESENTATIVE DIXIE: So based on the 21 study that you quoted that you gave us right here, 22 this doesn't sound like it's safe and effective if 2.3 it was stopped for adverse reasons. 2.4 DR. BOLES: It was stopped because two 25 of the patients who did not take the treatment had

1 to have a blood transfusion or surgery. Those were 2 patients that were not in the treatment arm. 3 were in the placebo arm. And the reason for stopping the study -- if you want to know what I 4 5 believe that you can conclude based on that is they didn't like the data. The adverse outcomes that 6 7 required intervention were in the group that did not get the reversal treatment. And the reversal 8 9 treatment, which they claim is not effective in 10 their six patients was shown to be more than 80 11 percent effective. I believe that's why the study 12 was stopped. 13 Representative Dixie? MR. CHAIRMAN: 14 REPRESENTATIVE DIXIE: One last 15 question. 16 You did mention that there were babies 17 delivered after this. Has there been any studies 18 or any follow up on how the babies are doing 19 emotionally, physically? Any kind of side effects since then? 2.0 21 MR. CHAIRMAN: Dr. Boles, you're 22 recognized. 23 DR. BOLES: The abortion pill reversal 2.4 mechanism involves a -- there's a website that 25 patients go to. Abortion providers don't tell

patients about the availability of this regimen.

The people who find it go to their smart phone or their iPad and they go to Google and they say, "Can an abortion pill be reversed?" The thing that pops up is abortionpillreversal.com, which is a free, nonprofit service that is provided to patients with a toll-free 24-hour-a-day hotline.

2.4

Through that hotline, the patients who are truly interested in pursuing reversal are connected with one of over 500 physician providers across the country who will prescribe this regimen for them. I'm one of those providers. The statistics on the outcomes of the patients who use that mechanism has been tracked and there are currently more than a thousand living, healthy babies with no increased risk of birth defects who have been delivered because patients have interacted with the abortion pill reversal hotline.

In fact, one other positive thing, other than saving the life of the baby, the progesterone supplementation early in the pregnancy according to our statistics of more than a thousand deliveries accomplished are that, when you look at the preterm delivery rates of those babies, the general preterm delivery rate in the United States

1 is about 10 percent. And for patients who use the abortion pill reversal regimen and are successful, 2 3 the preterm delivery rate is under 3 percent. 4 So not only are there no increase in birth defects and no increase in bad maternal 5 6 outcomes, there is a decrease in the risk of 7 preterm delivery, which is one of the biggest problems in children's health care in the country 8 9 and the number one cause of cerebral palsy in 10 America. 11 Representative Dixie? MR. CHAIRMAN: 12 REPRESENTATIVE DIXIE: I promise this is 13 my last question. 14 DR. BOLES: It's okay. 15 REPRESENTATIVE DIXIE: Currently, are 16 there any laws right now that prohibit you from 17 doing what you're doing now as far as giving these 18 two pills for this procedure? DR. BOLES: 19 No. 20 REPRESENTATIVE DIXIE: There's no --21 That's my last question. okav. 22 Thank you. Thank you, Mr. Chairman. 2.3 MR. CHAIRMAN: Thank you. To clarify on his point on this, the 2.4 25 study that had the six patients that got a placebo

1 and six patients that got progesterone as the 2 second pill, did they -- if they gave Cytotec, that was not part of those 12 patients; is that correct? 3 4 DR. BOLES: That's correct. It was not. 5 MR. CHAIRMAN: And so what you can take from that study would be that, if a patient was not 6 7 adequately informed and they were not compliant with their second pill that a portion of those may end up 8 9 in the ER but a significant portion would -- could 10 carry the baby to term and even a more significant 11 portion of those if the reversal pill was given 12 could carry that to term; is that correct? 13 DR. BOLES: Could you say that again? Ι 14 want to be sure I got it clearly. 15 MR. CHAIRMAN: Okay. So let's separate 16 them into three groups. The first group is they get 17 the abort- -- the first pill, mifepristone. 18 DR. BOLES: Yes. 19 MR. CHAIRMAN: And then they are compliant with the Cytotec then they would abort? 2.0 21 DR. BOLES: Yes. 22 MR. CHAIRMAN: If they were not 23 compliant, that would be the equivalent of the 2.4 placebo group and a significant portion of those 25 could carry to term. But based on that minor study,

1 a portion of those may end up in the ER and those 2 are the ones that got the blood transfusions and had to have the evacuation. 3 DR. BOLES: That is correct. 4 5 MR. CHAIRMAN: But if the patient was 6 informed that if they came back and had the reversal 7 pill, still, a small percentage may miscarry at that point in time but a significant portion of those 8 9 would carry to term? 10 DR. BOLES: That's correct. 11 MR. CHAIRMAN: All right. Thank you. 12 Representative Clemmons, you're 13 recognized. 14 REPRESENTATIVE CLEMMONS: Thank you, Mr. 15 Chairman. 16 And thank you for being here today. 17 DR. BOLES: Thank you. 18 REPRESENTATIVE CLEMMONS: I just want to 19 get some background. 2.0 You're an OB/GYN, you say? 21 DR. BOLES: Yes. 22 REPRESENTATIVE CLEMMONS: And how many 2.3 years have you been in practice? 2.4 DR. BOLES: I graduated from medical 25 school in 1992; so 28 years as a physician.

1 first four of those were my residency; so 24 years 2 in independent practice. 3 REPRESENTATIVE CLEMMONS: And during 4 that time frame, about how many abortions have you 5 performed? DR. BOLES: 6 None. 7 REPRESENTATIVE CLEMMONS: And are you not trained to do those or is that a --8 9 DR. BOLES: I chose not to participate 10 in the abortion training. 11 REPRESENTATIVE CLEMMONS: And this --12 these pills that we are discussing here, are they 13 FDA approved? 14 They are FDA approved, yes. DR. BOLES: 15 REPRESENTATIVE CLEMMONS: And how long 16 have they been FDA approved? 17 DR. BOLES: Since 2000. 18 REPRESENTATIVE CLEMMONS: Since 2000? DR. BOLES: Yes. 19 2.0 REPRESENTATIVE CLEMMONS: So you 21 discussed the clinical trials in 2012, what were the 22 trials before that were approved by the FDA? 2.3 MR. CHAIRMAN: Dr. Boles, you're 2.4 recognized. 25 DR. BOLES: The FDA trial that was

1 conducted by Danco, the pharmaceutical company, was the first trial and that resulted in the FDA approval. To my knowledge, there have been no further FDA sanctioned trials. The FDA did in the last few years based on data submitted by Danco broadened the indication for which mifepristone can In 2000, they approved it for up to seven be given. weeks and then a few years ago they broadened that to ten weeks. But that was not based upon any other brand new randomized trial.

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

2.0

2.1

22

23

2.4

25

The other trials which I discussed, the studies which were case series reports and other studies, were not conducted by the Food and Drug Administration or by Danco Pharmaceuticals. were conducted by the people who have developed the reversal regimen.

REPRESENTATIVE CLEMMONS: So with the reversal regimen itself, is that process -- I'm trying to get my head around the peer review depth or the depth of peer review on the reversal process itself as opposed to the separate pills.

DR. BOLES: The first study, the limited case series of only six patients that was published in 2012, was published in a peer review journal called The Annals of Pharmacotherapy. The largest

1 series of 754 patients who were evaluated in a more 2 structured manner was published in a peer review journal called Issues in Law and Medicine. 3 Where was 4 REPRESENTATIVE CLEMMONS: 5 that? Issues in Law and Medicine. DR. BOLES: 6 7 REPRESENTATIVE CLEMMONS: That's the 8 actual group? 9 DR. BOLES: That's the name of the 10 journal. 11 REPRESENTATIVE CLEMMONS: So the pills 12 themselves have been approved, but is the process 13 itself and the rate of success of the reversal, is 14 that approved in any way by the FDA, or is it just 15 standalone? 16 MR. CHAIRMAN: Dr. Boles, you are 17 recognized. 18 DR. BOLES: The Food and Drug 19 Administration does not require that prescription 2.0 medications be used only for their FDA approved 21 indications. Most prescriptions that you take may 22 be given for what are considered off-label 23 indications. Once a medication has been proven to 2.4 be safe and effective for the condition for which it 25 was originally approved, it can be used for any

1 other purpose for which it was approved or for which 2 it has been shown to be effective. Progesterone itself, natural 3 4 progesterone has been used in women's health for 5 over 50 years. If there are women in this room that are on a birth control method that's 6 7 prescribed that is anything other than a copper 8 IUD, they have a form of prescription progesterone 9 in their system right now. Menopausal women 10 receive progesterone. Progesterone has been 11 approved for use in pregnancy and is considered 12 Category B and has been shown to have no adverse 13 outcomes for use in pregnancy. In fact, is widely 14 used to prevent repetitive miscarriages and preterm 15 labor. So the medication does have approval for 16 use. There is not a problem with off-label use. 17 Have I answered your question? 18 MR. CHAIRMAN: Representative Clemmons, 19 you are recognized. 2.0 REPRESENTATIVE CLEMMONS: Thank you, Mr. 21 Speaker. 22 I'm not sure you have. So what I'm 23 getting at here is we're asking trained medical professionals to give patients advice about 2.4 25 something or recommend something or a process or

1 give women false hope, perhaps, about a process 2 that may or may not work, and I don't hear you saying that there is an overwhelming amount of peer 3 4 review study on the success rate of this process. 5 You discussed a 66 percent approval 6 rate of a very small pool. That gives me pause 7 when we are mandating creating a Class E felony for doctors who don't do this. But a medical 8 professional -- why would they ever give a patient 9 who is in an emotionally fragile state false hope 10 11 about something when the success rate is, A, so low 12 and, B, not substantively tested or thoroughly. 13 In your 20-plus years of practicing 14 medicine, how often have you given a patient advice 15 or a recommendation based on a test that was six 16 people deep with a two-thirds success rate? 17 MR. CHAIRMAN: Dr. Boles, you're 18 recognized. 19 DR. BOLES: You're forgetting the study that I quoted that has 754 patients still with a 2.0 2.1 68 percent success rate. That's almost three out of 22 four. Where if they don't get treatment, their rate 23 is pretty close to zero. Because without -- if you 2.4 take the mifepristone but do not take progesterone, 25 even if you don't take the Cytotec, the fetal

1 survival rate is as low as 8 percent. And that's a 2 report not from me or a pro-life physician. a report of analysis of the data that was published 3 4 by Dr. Daniel Grossman who is an abortion provider. And he wrote in a study that review of 5 the data shows that when a patient takes 6 7 mifepristone, the fetal survival rate can be as low as 8 percent. Our study of 754 patients published 8 in a peer review journal shows that the current 9 10 regimen that we recommend has a 66 to 68 percent 11 success rate. So I don't believe you can call it 12 false hope to increase the fetal survival from 13 8 percent to 68 percent. 14 And I don't believe that when a patient 15 changes their mind and you refuse to respect their 16 choice -- because that's what the abortion 17 providers tell us. This issue is all about, I 18 think, the patient's choice. If the patient 19 chooses to change her mind and is asked 2.0 specifically by a patient -- and is asked -- the 2.1 patient specifically asks the abortion provider if 22 anything can be done and they're told "no," then I 2.3 don't believe that is ethical. 2.4 MR. CHAIRMAN: Representative Clemmons, 25 you are recognized.

1 REPRESENTATIVE CLEMMONS: Thank you, 2 Mr. Speaker. 3 And, you know, you just told my 4 colleague over here that doctors can currently do 5 So you saying that we're refusing to respect this. 6 a patient's choice, I don't know if that's 7 occurring right now if you say it's already allowed to take place. 8 9 And my final question is do you intend 10 to perform any abortions in the future? 11 MR. CHAIRMAN: Dr. Boles. 12 DR. BOLES: No, I do not. 13 Representative Clemmons. MR. CHAIRMAN: 14 REPRESENTATIVE CLEMMONS: So you will 15 never be doing what you're asking other doctors to 16 do today? 17 DR. BOLES: I'm not asking any doctor to perform an abortion. I'm asking that the abortion 18 19 providers be required to answer the question 2.0 truthfully when a patient looks at them and says, 2.1 "I'm sorry that I took this. I want to change my 22 mind." I have delivered babies who have been 23 successfully reversed. I currently have two 2.4 patients that I'm following that I started on the 25 reversal protocol within the last three weeks.

1 I spoke to some of those patients 2 yesterday in preparation for this hearing today. told them that I would be coming here to testify 3 and I asked them -- I said, "Would you be in 4 support of a law that would require the abortion 5 6 provider to inform you at the time you take the 7 Mifeprex that, if you change your mind, there's a way to reverse it?" They all said, "Yes." 8 9 Patients who have been through this 10 process support this kind of legislation because 11 the other universal thing that I know in asking 12 every patient that the hotline has referred to me 13 that I ask them, "Did you ask your abortion 14 provider if there was a possibility of reversing 15 this?" And every single patient who asks that 16 question was told "no." Some of them were, in 17 fact, told that, if they didn't complete the 18 process, their baby would have birth defects and 19 that's dishonest because the FDA in it's pursual of 2.0 the approval for Danco's application asked Danco 2.1 "Are there any birth defects in the babies that 22 survive this process?" And Danco said "no." 23 REPRESENTATIVE CLEMMONS: And Danco --2.4 MR. CHAIRMAN: Representative Clemmons, 25 you are recognized.

1 REPRESENTATIVE CLEMMONS: And who is 2 Danco again? 3 DR. BOLES: Danco is the pharmaceutical 4 company that produces Mifeprex. REPRESENTATIVE CLEMMONS: That's 5 (indiscernible, simultaneous crosstalk) off the 6 7 medication? 8 DR. BOLES: I'm sorry? 9 REPRESENTATIVE CLEMMONS: No further 10 questions. 11 MR. CHAIRMAN: Okay. 12 Representative Byrd, you are 13 recognized. 14 REPRESENTATIVE BYRD: Thank you, 15 Mr. Chairman. 16 Is there any research that has been 17 done that shows what percent of women, if they had 18 known about this reversal process, would have not 19 followed through with abortion? 2.0 DR. BOLES: Could you repeat that? REPRESENTATIVE BYRD: Yeah. Is there 21 22 any research that has shown what percentage of women, if they had known about this reversal 23 2.4 process, would have not followed through with the 25 abortion?

1 MR. CHAIRMAN: Dr. Boles, you are 2 recognized. 3 DR. BOLES: I'm not sure that I can answer that. 4 There's not information that gives us a specific percentage of the number of women who 5 regret what they have done after they take the pill. 6 7 What I have learned in talking to many of these patients over the three or four years that I have 8 been part of the Abortion Pill Reversal network is 9 10 that there are women who do take the pill and 11 immediately regret it. 12 In fact, one that I talked to less than 13 two weeks ago was -- had found the hotline on an 14 internet search and was calling it begging for help 15 less than an hour after taking the first pill in 16 the series. 17 So can I tell you what the percentage 18 of women who take medication abortion pills then 19 regret it? No. I can't tell you that. Can I tell 2.0 you that there are a decent number of people that 2.1 do? Absolutely. The hotline gets at least a dozen 22 phone calls a day and on busier days of the week 23 sometimes considerably more than that. So there

are patients who seek this out and they find it not

because they are informed of it at their abortion

2.4

25

1 provider but because they find it themselves. 2 So we have no way of knowing how many people didn't find this method and simply completed 3 4 the abortion process even though they regretted it. 5 There's no way to know that information. MR. CHAIRMAN: Representative Byrd, you 6 7 are recognized. REPRESENTATIVE BYRD: No further 8 9 questions. 10 MR. CHAIRMAN: Okay. 11 Chairman [sic] White, you are 12 recognized. 13 REPRESENTATIVE WHITE: Thank you, 14 Chairman. 15 Just for clarity on my part. What is 16 the time period between administration of the 17 mifepristone and the Cytotec if you're going 18 through the complete process? DR. BOLES: 19 24 to 48 hours. 2.0 REPRESENTATIVE WHITE: 24 to 48 hours. 21 And I think you said this three times, 22 but I just want to make sure I understood 23 correctly. 2.4 If a dose of mifepristone is 25 administered, it can be reversed with a regimen of

1 But without the progesterone, then progesterone. 2 it can be harmful to the woman unless she completes 3 the Cytotec? DR. BOLES: Yes. 4 So the woman who 5 changes her mind after taking the mifepristone and decides that she's not going to take the Cytotec and 6 7 hope for the best because she doesn't know there's a 8 better option, she is at risk. So when the patients leave the abortion clinic and don't know that there 9 10 is an option to reverse and they simply think they 11 can figure out what to do on their own, those are 12 the women who are in danger. 13 REPRESENTATIVE WHITE: Thank you. 14 MR. CHAIRMAN: Representative Sherrell, 15 you are recognized. 16 REPRESENTATIVE SHERRELL: Thank you, 17 Chairman. 18 Thank you, Dr. Boles for being here 19 today. 2.0 And my question is I believe you said 21 you never have performed any abortions? 22 DR. BOLES: Correct. 2.3 REPRESENTATIVE SHERRELL: I just want to 2.4 say you're my kind of doctor, and I appreciate what 25 you stand for and appreciate you being here today,

1 and I appreciate you protecting life inside the 2 mother's womb. Thank you for being here today. 3 DR. BOLES: Thank you, sir. Representative Dixie, you 4 MR. CHAIRMAN: 5 are recognized. REPRESENTATIVE DIXIE: You referenced 6 7 two different studies. The one with 754 and the one with 6 or 12. Was the 700- -- the study with the 8 9 754, was it conducted under the same conditions as 10 the one with 12? Are we comparing apples to apples 11 here or are they two different studies with two 12 different scopes? 13 MR. CHAIRMAN: Dr. Boles, you are 14 recognized. 15 DR. BOLES: They are two different 16 studies conducted by two different people with two 17 different purposes. The first study that I 18 referenced released in 2012 only had six patients 19 and it was not a case controlled-type study. 2.0 simply reported a series of six patients in whom 2.1 reversal was attempted and in whom four of the six 22 were successful. There were two other small studies that 2.3 2.4 were published, which I don't have with me today. 25 And then there was a final study by the creators of

1 the reversal regimen that you do have in the folder 2 that I gave you published by Dr. George Delgado in a peer review journal in which he evaluated 754 3 4 patients that wished to reverse the effects of the mifepristone. They did not take their Cytotec and 5 they took progesterone in a variety of different 6 7 They were randomized to receiving an regimens. injection versus an oral regimen and there were 8 different oral regimens that were used. 9 10 This study of nearly a thousand 11 patients did show that the most effective regimen 12 is now the one we currently recommend and that it 13 has a 68 percent success rate with no increase in 14 birth defects and no increase in adverse outcomes 15 for the woman. 16 The final study you've asked about was 17 conducted by an abortion doctor who randomized 12 18 women that sought an abortion into two groups of 19 six each. Some received the abortion pill only and 2.0 placebo; some received the abortion pill and the 2.1 reversal regimen that we currently recommend. 22 Those were the studies that I've referenced. 23 MR. CHAIRMAN: Representative Dixie, any 2.4 further question? 25 REPRESENTATIVE DIXIE: (No audible

1 response.) 2 MR. CHAIRMAN: Okay. Thank you. 3 Chairman Smith, you are recognized. 4 REPRESENTATIVE SMITH: Thank you, Dr. Boles. 5 Just as clarification, if this were 6 7 taken out of the scope of treating abortion, would this be viewed as just simply informed consent, 8 9 talking with a patient about the options that they 10 have as a standard approach to care if it were 11 removed from the abortion issue? Because I know 12 that's what is so controversial in the minds of 13 many. But if you remove this practice of informing 14 and giving full information to the patient in any 15 other scope of care, would this just be considered 16 informed consent in a standard practice of care? 17 DR. BOLES: Absolutely. That's -- that 18 is one of my points. 19 REPRESENTATIVE SMITH: Thank you, Dr. 2.0 Boles. 21 DR. BOLES: For example, if a patient 22 comes to me and she wants to have her tubes tied, my 2.3 informed consent process with her is similar to what 2.4 should occur with the informed consent process for 25 the abortion pill. I say to her, "Are you sure you

1 don't want anymore children because you have to consider this method of birth control to be 2 irreversible." 3 And then I go on to tell her, "You have 4 5 probably heard of people having their tubes put back together. That is possible but it only works 6 7 about 50 percent of the time and you can't use this as your method of birth control if you're going to 8 think about doing that in the future. That would 9 10 not be a good choice." That's my informed consent 11 process before tying a woman's tubes. 12 In a similar fashion, basic ethical 13 requirements for informed consent on taking an 14 abortion pill should say that if you take this and 15 regret it afterwards, there is a way to try to 16 reverse it. It won't always work, but you can try 17 it and here is how you access that information. That process can be completed, as I just stated in 18 19 less than 15 seconds and in no way is an undue 2.0 burden on either the woman or the abortion 21 provider. It's simply medical ethics. 22 MR. CHAIRMAN: Chairman Smith, you are 23 recognized. 2.4 REPRESENTATIVE SMITH: Thank you, 25 Doctor, and thank you Mr. Chairman for sponsoring

1 this bill. This is good standard of practice and 2 good standard of care, and I think this is an easy 3 vote for this member. Thank you. 4 Thank you. Thank you. 5 MR. CHAIRMAN: Representative Miller, you are 6 7 recognized. 8 REPRESENTATIVE MILLER: Thank you, 9 Mr. Chair. 10 Mr. Chairman, I think last week in 11 subcommittee we heard from a female physician. 12 Will we hear from her while we are out of session? 13 Thank you. She was MR. CHAIRMAN: 14 supposed to be on the schedule for today. She was 15 on the schedule for last week. And I do not see her 16 in the audience, and I do not know that we have 17 anyone on the other -- that may want to testify 18 while we are out of session. 19 REPRESENTATIVE MILLER: Thank you, 2.0 Mr. Chairman. 21 Doctor, thank you for your 22 presentation. 2.3 Do you support a woman's right to 2.4 choose to have an abortion or not have an abortion? 25 DR. BOLES: I support the woman's right

1 to access birth control and to make the decisions 2 about whether or not to become pregnant. But once another life is involved -- because science and 3 4 ethics are very clear that human life begins at conception -- once another life is involved, I do 5 6 not support abortion as a human right in any case 7 other than to save the life of the mother, which is 8 an extremely rare occurrence. 9 Representative Miller, MR. CHAIRMAN: 10 you are recognized. 11 REPRESENTATIVE MILLER: However, you 12 support the right of the woman to change her mind in 13 a case of reversal? You support her right to choose 14 to change her mind? 15 DR. BOLES: When she is making the choice to save the life of a child that she thought 16 17 a moment before that she didn't want then, yes, I 18 support that. Because that choice potentially saves 19 a life. The choice to abort the pregnancy always ends a life. 2.0 There's a vast difference between 21 those two positions. 22 Representatives Miller? MR. CHAIRMAN: 2.3 REPRESENTATIVE MILLER: Thank you, 2.4 Mr. Chairman. Thank you. 25 MR. CHAIRMAN: Thank you.

1 Representative Cooper, you are 2 recognized. 3 REPRESENTATIVE COOPER: Thank you Mr. Chairman. 4 5 I apologize, everyone. I had to run 6 out to present a bill in another committee and 7 that's why I was not here and I missed part of your 8 presentation. 9 I want to know -- this pill that is 10 allowed right now it does destroy -- prevents a 11 baby from being born. In other words, it kills the 12 embryo. 13 DR. BOLES: Yes, it does. 14 REPRESENTATIVE COOPER: And I know there 15 may be a lot of studies because, like I said, I 16 missed part of your presentation. 17 If it kills the baby, what does it do 18 to the mother? 19 DR. BOLES: The application that Danco 2.0 Pharmaceuticals made to the Food and Drug 2.1 Administration would lead you to believe that there 22 are very few side effects or adverse outcomes for 23 the mother. However, there have been women who as a 2.4 result of unusual infections after the use of this 25 medication, and there are many women who have had

bleeding that require transfusion or surgery afterwards.

2.0

2.1

2.4

And, you see, the problem here is that while 29 states require that the complications of abortions be reported to the State's Department of Health or to the Center for Disease Control, 21 states don't require reporting at all. And of the 29 who do, the enforcement mechanisms in those states have no teeth. So we don't have accurate information on how often women experience bad complications from use of this abortion regimen.

There are a number of reports to the Food and Drug Administration of adverse events. But the vast majority of these adverse outcomes and complications were not reported by abortion providers. They were reported by emergency room doctors and private OB/GYNs like myself to the adverse event reporting database. That data with several thousand adverse outcomes is currently being analyzed by a group of which I am a part and we expect publication to occur later this year on a more accurate incidence of adverse outcomes using the medication abortion regimen.

So in answer to your question, yes, there are the potential for bad outcomes for women

1 who use this medication. 2 REPRESENTATIVE COOPER: Okay. Earlier 3 you said --4 MR. CHAIRMAN: Representative Cooper, 5 you are recognized. REPRESENTATIVE COOPER: Do you mean that 6 7 mothers have lost their lives? DR. BOLES: Some mothers have. A few 8 mothers have lost their lives. Most of those deaths 9 10 have occurred because of atypical infections that 11 typically are only seen after the use of medication 12 abortion. But there -- there's the potential as 13 well for death from blood loss or other problems. 14 REPRESENTATIVE COOPER: One moment, Mr. 15 Chair, and I'll be finished. 16 And with that few, do you have a 17 number? 18 DR. BOLES: I do not have a number. That's what we're working on. The group that I'm a 19 2.0 part of is working on a number. 21 REPRESENTATIVE COOPER: Thank you, Mr. Chair and thank you for being here. 22 2.3 MR. CHAIRMAN: Thank you. 2.4 I have one clarification on something 25 that you answered for her. She had asked if the

1 first pill, mifepristone, damaged the baby -- I 2 think is what she said. I think -- would it be more clear to say that that pill creates an 3 4 environment that's not conducive to the baby 5 therefore that damages the baby as opposed to 6 specifically it damaging the baby? 7 DR. BOLES: The pill -- the intended 8 effect of the pill is to kill the child, and it accomplishes this by interfering with the action of 9 10 progesterone. That action reduces the blood supply 11 into the uterus which causes the placental tissue to 12 become unstable and it deprives the placenta and the 13 embryo or fetus of oxygen and other critical 14 nutrients. That's the -- if you want to call it, 15 embryocidal or feticidal. That's the feticidal 16 effect. 17 MR. CHAIRMAN: Thank you. 18 Representative Dixie, you have another 19 question? 2.0 REPRESENTATIVE DIXIE: Yes. 21 Are you familiar with the report that 22 was produced by the Louisiana Department of Health 23 which did a study based on the effects of abortions 2.4 induced with drugs and chemicals if they can be 25 reversed and to report the findings to their state

1 and house committees? Are you familiar with that? 2 3 DR. BOLES: I was not aware that Louisiana had undertaken that. 4 REPRESENTATIVE DIXIE: Okay. 5 Well, 6 after that study they have several experts -- seven, 7 I think, to be exact -- you know, from medical fields, OB/GYN, pharmacies -- they had an array of 8 9 panels. And the conclusion was that there was 10 11 neither sufficient evidence or a scientific basis 12 to conclude that the abortion induced with drugs or 13 chemicals can be reversed. So I think what you're 14 asking -- to go along with what Representative 15 Clemmons was saying -- we're asking to set a 16 standard on something that cannot be proven that's 17 not safe. And even if you do 754 people at 68 18 percent of that, I don't think that's 19 representative to be asking people to -- for us to 2.0 mandate something that's not proven or recommend 21 something that's not proven. 22 MR. CHAIRMAN: Dr. Boles, you are 23 recognized. 2.4 DR. BOLES: To specifically answer that, 25 I would have to see how the Louisiana Department of

1 Health arrived at their conclusions because I 2 would -- with what you have stated about their conclusions, I would vigorously disagree. 3 4 You know, the abortion industry -- you 5 keep focusing on 754 patients not being enough. But the abortion industry and Dr. Creinin want us 6 7 to conclude that this is not safe based on a series 8 of 12 patients. Which is it? 9 MR. CHAIRMAN: Representative Dixie, you 10 are recognized. 11 REPRESENTATIVE DIXIE: I don't want to get confused or lost in confusion. But I just want 12 to make it clear that I believe that the one that 13 14 was based on the six patients was stopped because of 15 the risk of the health for women. The one at 754, 16 I'm not sure -- I don't think that there's enough 17 information out there to be making this -- to make 18 this a mandate. That is my question. 19 If one was stopped due to concerns of 2.0 health of women in this particular trial, I think 2.1 that there's something that maybe we should take 22 some time to even -- maybe we should look at to get 23 the members to look at the report that the 2.4 Louisiana Department of Health put forth so we can 25 be a little bit more informed before we make this

decision.

2.0

2.1

2.3

2.4

DR. BOLES: In response to that, again, the study was stopped because two of the six women in the group who only took the abortion pill had a bad outcome. The six women in the group that took the progesterone to reverse it did not have bad outcomes. Five of the six had surviving embryos and none of the six required a blood transfusion or a surgery. The only two adverse outcomes were in the group that took the abortion pill without the reversal regimen and one of them required surgery and the other one required surgery and a blood transfusion.

So if we want to draw a conclusion from a series of 12 patients that was stopped, it was stopped because the ones that didn't get the reversal regimen did not do well. That's the real conclusion that you can draw from that study. And from a study of 754 patients that show no increase in bad outcomes for the women who try reversal and show a 68 percent success rate at saving the baby's lives, I think that speaks for itself.

MR. CHAIRMAN: All right. Thank you. I think we got one last -- Chairman [sic] Kumar and then we are going -- I think everybody has had their

1 questions and we are going to wrap this up. 2 But, Chairman Kumar, you are 3 recognized. 4 REPRESENTATIVE KUMAR: Thank you, Thank you for your generosity. 5 Mr. Chairman. Dr. Boles, thank you for being here. 6 DR. BOLES: You're welcome. 7 8 REPRESENTATIVE KUMAR: I think stopping 9 the study is required as a humane gesture or the 10 responsibility to our patients when the outcomes are 11 so clear. And that's not an uncommon phenomenon, is 12 it? 13 DR. BOLES: That's correct. 14 REPRESENTATIVE KUMAR: Providing a 15 patient with full information is part of the 16 informed consent. You know, medication you're 17 taking, can it be the worst, what side effects does 18 That should be a part of the informed it have? 19 consent. And it's very good that we are -- we have 2.0 legislation to this regard so this process does not 2.1 get overlooked. But certainly, this should really, 22 in a way, should not be necessary if we were all to 23 inform the patients completely of the effects of 2.4 what treatment we are giving them and the 25 possibilities of reversal.

1 These are remorseful and intense in 2 overwhelming times, and these are patients, in my 3 opinion that certainly need complete information and reassurance that it's an uncertain territorial 4 acting and certainly the situation can be rescued 5 if need be, if they change their mind. 6 7 My last question to you is is there knowledge within the studies and science at this 8 time about babies that were delivered following the 9 10 reversal process? How old are they now and are 11 there any health consequences to them? 12 MR. CHAIRMAN: Dr. Boles, you are 13 recognized. 14 DR. BOLES: The first one would have 15 been delivered in 2007 or 2008, so we now have a 16 teenager that was successfully reversed. And since 17 then, there are over a thousand reported deliveries 18 and then there are some women who did not follow up. 19 Of the ones that we have been able to follow, of the 2.0 ones that have been -- that it's been possible to 2.1 track, there is no increase in the number of problems that the child has from the standpoint of 22 23 birth defects or developmental issues or behavioral

2.4

25

issues.

///

None.

1 In fact, the statistic I mentioned 2 earlier gives -- shows another benefit to using this and perhaps that will someday be broadened to 3 4 all pregnancies. But when you have the preterm delivery rate being around 10 percent with 5 premature delivery being responsible for an 6 7 enormous number of health care problems and the expenditure of an enormous amount of health care 8 9 dollars, this regimen appears to reduce the preterm delivery rate from 10 percent down to less than 10 11 3 percent. 12 So there have been no adverse outcomes 13 for the babies noted either development or behavior 14 or birth defects. And there is -- there are two 15 very significant benefits that have been shown. 16 One, saving the baby's life 68 percent of the time. 17 And, two, reducing the preterm delivery rate. 18 REPRESENTATIVE KUMAR: Thank you, Dr. We are grateful for your presence and your 19 Boles. 2.0 knowledge. Thank you. 21 DR. BOLES: Thank you. 22 MR. CHAIRMAN: All right. Thank you. 23 appreciate your testimony. 2.4 And seeing no further questions, we 25 will go back into session.

```
1
                We are back on the amendment. We have
 2
   a -- the question has been called on the amendment
 3
    without objection. We are voting on Amendment
    014982.
 4
5
                All those in favor say "aye."
                COMMITTEE MEMBERS: (Collectively) Aye.
 6
 7
                MR. CHAIRMAN: Opposed?
8
                COMMITTEE MEMBERS: (No audible
9
   response.)
10
                MR. CHAIRMAN: Ayes have it.
11
    amendment goes on the bill.
12
                I believe we have a second amendment by
13
   Representative Dixie.
14
                Do you plan to run that amendment?
15
                REPRESENTATIVE DIXIE: If I can explain
16
    it.
17
                MR. CHAIRMAN: Okay. It is Amendment
18
    015380.
19
                UNIDENTIFIED SPEAKER: Motion on
2.0
   amendment.
21
                UNIDENTIFIED SPEAKER: Second.
22
                MR. CHAIRMAN: Okay. You have a motion
23
   and a second.
2.4
                REPRESENTATIVE DIXIE: So with the
25
   previous amendment, I think there's some signage --
```

```
1
   well, with this bill there's going to be some
 2
    signage that's going to be in waiting rooms or in
 3
    the physician area. So this will just require some
    additional language to put a warning to patients
 4
    that there have been no medical trials completed
5
    that prove a medication abortion can be reversed.
 6
 7
   And that's simply what my amendment does -- add
   verbiage.
8
9
                MR. CHAIRMAN: Okay. Chairman Hill,
10
   you're recognized on the amendment.
11
                CHAIRMAN HILL:
                                Thank you very much.
12
                In light of the fact that we just spent
13
    50 minutes to the contrary of what this amendment
    says, I move to table Amendment Number 2.
14
15
                UNIDENTIFIED SPEAKER: Second.
16
                MR. CHAIRMAN: Okay. Proper motion.
17
                With that, we will be voting on the
18
    tabling motion.
                All those in favor of tabling Amendment
19
2.0
    015380 say "aye."
2.1
                COMMITTEE MEMBERS: (No audible
22
    response.)
23
                MR. CHAIRMAN: Debate is off all except
2.4
    for the sponsor before we go to the tabling motion.
25
                REPRESENTATIVE DIXIE: We did talk about
```

the clinical trials, but there is nothing that has 1 2 been successfully proven that this is very effective for women in these trials. I think that it's not 3 sufficient enough, and I think that this verbiage is 4 5 very important to go on the signage as well. And with that, that's all I have to say 6 7 on this and thank you, Mr. Chairman, for giving me a second to speak about this. 8 9 MR. CHAIRMAN: Thank you. With that, we 10 will be voting on the tabling motion. 11 All those -- we are tabling 015380. 12 All those in favor of tabling the amendment, vote 13 "aye." 14 COMMITTEE MEMBERS: (Collectively) Aye. 15 MR. CHAIRMAN: Opposed? 16 COMMITTEE MEMBERS: (Collectively) No. 17 MR. CHAIRMAN: Ayes have it. We have 18 tabled the amendment. 19 We are back on House Bill 2568 as 2.0 amended. 21 Chairman Faison, you are recognized. 22 REPRESENTATIVE FAISON: I renew my 2.3 motion. 2.4 MR. CHAIRMAN: Chairman White, you are 25 recognized.

1 REPRESENTATIVE WHITE: Thank you, 2 Chairman. 3 Just one more time, based on the 4 question I asked our guest, would you just restate 5 what the signage says in the original bill in the 6 amendment that we just passed? 7 REPRESENTATIVE FAISON: Thank you, Chairman White. 8 This bill would provide -- or require 9 10 abortion facilities to post both signage in the 11 facilities as well as give verbal information to 12 women about the procedure as well as how and where 13 they can procure the abortion pill reversal if they 14 so choose. 15 MR. CHAIRMAN: Thank you. 16 Representative Clemmons, you are recognized. 17 REPRESENTATIVE CLEMMONS: Thank you, 18 Mr. Chairman, and thank you sponsor. 19 I appreciate what I believe is your 2.0 intent with this legislation. I did raise the 2.1 issue earlier of false hope. And I have a sincere concern about that, and I know that your intent 22 2.3 with this legislation is not to increase the number 2.4 of women who come in thinking that if they change 25 their mind they can just reverse that. I think

that could be an effect to this legislation that may not be considered for, you know, this body has spent during my tenure a lot of time limiting the constitutional rights of women. And this bill seems to do the reverse of that or could have the effect of doing the reverse of that.

2.0

2.4

And I'm reading this notice that's to be posted in the doctors' offices, and I think the language of it is very telling because we've talked a lot about the medical studies or lack thereof and sample sizes. And I just want to read this.

"Recent developing research has indicated that mifepristone alone is not always effective in ending a pregnancy. It may be possible to avoid." There seems -- there's a lot of iffy language in this notice.

And this is a pretty thoroughly drafted piece of legislation. You've got down to the font of what it has to say on the website and so forth.

Are you concerned, given what we've heard today, the testimony I think you heard in the subcommittee from both sides and just the language of this legislation that you are providing women who are already in an emotional state making probably, I would argue, the most difficult

decision in their life. Are you concerned you're 1 2 giving them false hope? 3 MR. CHAIRMAN: Chairman Faison, you are 4 recognized. 5 REPRESENTATIVE FAISON: Thank you, Mr. Chairman. 6 7 The gentleman from Shelby County -- I mean from Davidson County, I will remind you that 8 9 two years ago in Washington D.C. in a very 10 bipartisanship manner, every democrat and 11 republican alike in the House and the Senate, which 12 is an extreme rarity, they voted for a law called 13 Right to Try. And that would give Americans the 14 ability to enter in and try some medical treatment 15 that may or may not work. It could possibly give 16 them false hope, but it could also possibly give 17 them hope. I would encourage you that this is not 18 what we're doing here. 19 This is not 100 percent. Very few 20 things in medicine are 100 percent. But there are 2.1 times that a young lady -- and I have actually 22 spoken with some -- that they were devastated by 23 what they did, they got scared, they got pressured, 2.4 by people -- maybe pressured by a perpetrator, and 25 they realized, "You know what, I need a chance.

1 at least, can try to undo this." And I'm also intrigued that someone 2 such as yourself who is a champion -- so-called 3 4 champion for women's right to choose, would want to 5 deny them the ability to understand that this is a choice that they can make. This is another choice 6 7 to provide for them. So I'm not challenged at all that this 8 9 isn't 100 percent. I'm encouraged that there is a 10 possibility and that this could save a life and 11 that we're giving a mom another choice. 12 MR. CHAIRMAN: Represent Clemmons. 13 REPRESENTATIVE CLEMMONS: Thank you, Mr. 14 Chairman. 15 And thank you for that response. 16 guess my concern is to address your last point. 17 Nothing in the law prohibits this from taking place 18 right now. I think it's up to the medical 19 professional's discretion. And right now we are 2.0 adding something into the standard of care or 2.1 seeking to -- it appears to add something into the 22 standard of care of medical professionals who, you 23 know, they are not prevented from doing this 2.4 already. 25 So I don't think that we are standing

1 in the way or that the law prohibits this or stands in the way in any respect. And, you know -- and I get that there's two sides to this issue, and I 3 4 certainly never heard from a woman who has been 5 denied that opportunity. You very well may have as 6 you said. 7 The other issue I want to address here is we are creating a Class E felony in civil 8 9 liability even with the award of attorney's fees in 10 this legislation. I assume that's your attempt to 11 put some teeth into this and force medical 12 professionals to comply with it. But, you know, 13 this body has decimated medical malpractice in the 14 State of Tennessee. 15 And so really the teeth you're seeking 16 to put into it, because of our medical malpractice 17 laws and tort reform, the teeth that I think you're 18 intending to put into this law is virtually 19 nonexistent because of the high hurdles that we 2.0 have in the State of Tennessee in that respect. 21 So I just point that out to you, and I 22 don't know that a response is necessary. But thank 2.3 you very much, and I appreciate your time, 2.4 Mr. Chairman.

MR. CHAIRMAN:

Thank you. Any further

25

```
questions?
 1
 2
                Seeing none, we are voting on House
    Bill 2568.
 3
                All those in favor, say "aye."
 4
 5
                COMMITTEE MEMBERS: (Collectively) Aye.
                MR. CHAIRMAN: Ayes have it. The bill
 6
 7
    moves on to Calendar and Rules.
 8
                If you wish to be recorded as a "no"
    please -- or have your vote recorded, please tell
 9
10
    the clerk.
11
                 (WHEREUPON, the foregoing proceedings
12
    were concluded.)
13
14
15
16
17
18
19
20
21
22
23
2.4
25
```

1	REPORTER'S CERTIFICATE
2	STATE OF TENNESSEE
3	COUNTY OF MONTGOMERY
4	
5	I, D. ROCHELLE KOENES, Licensed Court
6	Reporter, with offices in Clarksville, Tennessee,
7	hereby certify that I transcribed the audio
8	recording of LEGISLATIVE HISTORY HOUSE HEALTH
9	COMMITTEE - HB2568 by machine shorthand to the best
10	of my skills and abilities, and thereafter the same
11	was reduced to typewritten form by me.
12	I further certify that I am not related
13	to any of the parties named herein, nor their
14	counsel, and have no interest, financial or
15	otherwise, in the outcome of the proceedings.
16	I further certify that in order for this
17	document to be considered a true and correct copy, it must bear my original signature, and that any
18	unauthorized reproduction in whole or in part and/or transfer of this document is not authorized,
19	will not be considered authentic, and will be in violation of Tennessee Code Annotated 39-14-104,
20	Theft of Services.
21	DROWN KOONON
22	D. ROCHELLE KOENES - RPR - LCR
	Veteran Court Reporting
23	Court Reporter and Notary Public State of Tennessee
24	notary rubite beate of remiesbee
25	My Notary Public Commission Expires: 04/10/2023 LCR# 689 Expires: 6/30/2021

2568 2:10,16,23 administering **abort-** 16:17 48:19 54:3 7:22 **abortion** 2:25 3:6 **28** 17:25 4:25 5:3,9,10 7:2, administration **-14982** 3:13 10,16 8:3,6,7 5:12 19:14 20:19 **29** 37:4,8 28:16 36:21 37:13 13:23,25 14:4,18 15:2 18:10 23:4, 0 adverse 6:10 3 16,21 24:18 25:5, 11:13 12:8,23 13 26:19,25 27:9, **0148** 3:13 13:6 21:12 31:14 18,25 28:4 29:9 **3** 15:3 45:11 36:22 37:13.14. 014982 3:14 46:4 31:17,18,19,20 18,19,22 42:9 32:7,11,25 33:14, **015380** 46:18 45:12 4 20 34:24 35:6 47:20 48:11 37:11,15,23 38:12 advice 21:24 **40** 11:11 12:1 40:12 41:4,6 42:4, 22:14 1 10 47:6 49:10,13 **48** 3:2 5:25 28:19, advisory 4:24 abortionpillrever alike 51:11 **1** 2:16 **sal.com** 14:5 allowed 24:7 **1.1.1** 10:4 5 abortions 18:4 36:10 24:10 29:21 37:5 **1.1.3** 10:4 **AMA** 10:12 39:23 50 21:5 33:7 47:13 **10** 2:6 15:1 45:5, amended 48:20 Absolutely 27:21 500 14:10 10 32:17 amendment 100 51:19,20 52:9 academic 4:20 3:10,13,16,17,21, 6 **12** 8:5.13 16:3 23 46:1,2,3,11,12, access 33:17 30:8,10 31:17 14,17,20,25 47:7, 6 30:8 35:1 41:8 42:15 10,13,14,19 66 22:5 23:10 48:12,18 49:6 accomplished **15** 4:19 33:19 14:23 **68** 6:7 7:15 10:1 America 15:10 **1992** 17:25 22:21 23:10,13 accomplishes American 8:2 31:13 40:17 42:21 39:9 10:3 2 45:16 accurate 10:6 Americans 51:13 37:9,22 **2** 47:14 7 amount 9:6 22:3 acting 44:5 20 4:18 45:8 action 5:19 39:9, **700-** 30:8 **20-plus** 22:13 analysis 23:3 10 **754** 7:14 20:1 **2000** 5:11 18:17, analyzed 37:20 actual 20:8 22:20 23:8 30:7,9 18 19:7 and/or 12:16 31:3 40:17 41:5, add 47:7 52:21 2007 6:14 44:15 15 42:19 **Annals** 19:25 adding 52:20 2008 44:15 anymore 33:1 addition 4:20 8 2012 7:1 8:9 18:21 apologize 36:5 19:24 30:18 additional 47:4 **8** 23:1,8,13 appears 45:9 **2020** 2:6 address 52:16 52:21 80 9:4 10:2 13:10 53:7 **21** 37:6 **apples** 30:10 adequately 16:7 **24** 5:25 18:1 Α application 25:20 28:19,20 administer 6:6 36:19 24-hour-a-day ability 51:14 52:5 administered appointments 14:7 28:25 abort 16:20 35:19 4:21

approach 32:10 bleeding 8:19 51:12 В 9:6,13 11:18,23 approached calling 27:14 12:2,11,12 37:1 6:16,21 calls 27:22 **babies** 7:9 13:16, blocker 5:16 approval 19:3 18 14:16,24 24:22 care 15:8 32:10, blood 9:10 12:14, 21:15 22:5 25:20 25:21 44:9 45:13 15,16 34:2 45:7,8 16 13:1 17:2 approved 5:12 52:20,22 baby 6:20 7:18 38:13 39:10 42:8, 18:13,14,16,22 14:20 16:10 25:18 12 Carolina 6:15 19:7 20:12,14,20, 36:11,17 39:1,4,5, board 4:17,24 25 21:1,11 carry 16:10,12,25 17:9 area 47:3 **body** 50:2 53:13 baby's 42:21 **case** 6:24 7:1,3,6 45:16 argue 50:25 **Boles** 4:13,16,17 8:8 19:12,23 11:2,8,21 12:5,9, **back** 12:4 17:6 arm 11:9 13:2,3 30:19 35:6,13 24 13:21,23 33:6 45:25 46:1 **array** 40:8 15:14,19 16:4,13, **cases** 5:22 48:19 18,21 17:4,10,17, arrived 9:7 41:1 Category 21:12 background 21,24 18:6,9,14, 17:19 asks 23:21 25:15 17,19,23,25 19:22 Center 37:6 20:6,9,16,18 **bad** 15:5 37:10,25 aspiration 9:14 cerebral 15:9 22:17,19 24:11, 42:5,6,20 12,17 26:3,8,20 **Associations** certified 4:18 **based** 8:4 12:20 27:1.3 28:19 29:4. 10:3 Chair 34:9 38:15, 13:5 16:25 19:5,9 18,22 30:3,13,15 **assume** 53:10 22 22:15 39:23 41:7, 32:5,17,20,21 14 49:3 34:25 35:15 attempt 2:23 Chairman 2:14, 36:13,19 38:8,18 12:19 53:10 19,20 3:10,14,20 **basic** 6:2 33:12 39:7 40:3,22,24 4:9 10:13,19 attempted 8:23 **basis** 40:11 42:2 43:6,7,13 13:13,21 15:11, 30:21 44:12,14 45:19,21 22,23 16:5,15,19, begging 27:14 attempting 8:5 22 17:5,11,15 **born** 36:11 begin 7:20 18:23 20:16 21:18 attorney's 53:9 **brand** 19:10 22:17 23:24 begins 35:4 atypical 38:10 24:11,13 25:24 **break** 8:20 behavior 45:13 26:11,15 27:1 audible 31:25 **Brent** 4:13,17 28:6,10,11,14 behavioral 44:23 46:8 47:21 29:14,17 30:4,13 broadened 19:6, benefit 45:2 audience 34:16 31:23 32:2,3 8 45:3 33:22,25 34:5,10, benefits 45:15 audio 2:4 brought 2:23 13,20 35:9,22,24, biggest 15:7 25 36:4 38:4.23 authored 8:3 **burden** 33:20 39:17 40:22 41:9 **bill** 2:10,12,16,23 availability 14:1 **busier** 27:22 42:23,24 43:2,5 3:6,11 5:2 34:1 44:12 45:22 46:7, avoid 50:15 36:6 46:11 47:1 **Byrd** 26:12,14,21 10,17,22 47:9,11, 48:19 49:5,9 50:4 28:6,8 award 53:9 16,23 48:7,9,15, 54:3.6 17,21,24 49:2,8, aware 9:24 40:3 bipartisanship C 15,18 51:3,6 **aye** 46:5,6 47:20 51:10 52:12,14 53:24,25 48:13,14 54:4,5 54:6 calendar 2:15 **birth** 7:18 14:16 Ayes 46:10 48:17 54:7 15:5 21:6 25:18, challenged 52:8 54:6 21 31:14 33:2,8 call 23:11 39:14 champion 52:3,4 35:1 44:23 45:14 **called** 5:13,15,25 chance 51:25 bit 41:25 19:25 20:3 46:2

change 3:4,9 5:5 **code** 3:13,14 conditions 30:9 creates 39:3 6:17 23:19 24:21 10:3,12 conducive 39:4 creating 22:7 25:7 35:12,14 colleague 24:4 53:8 44:6 49:24 conducted 19:1, Collectively 46:6 creators 30:25 13,15 30:9,16 changed 6:3 48:14,16 54:5 31:17 Creinin 8:3 9:17 chemicals 39:24 College 4:23 8:2 conducting 11:9 41:6 40:13 11:12 critical 39:13 comments 3:17 child 35:16 39:8 confused 41:12 criticism 7:28:8 44:22 committee 2:5, 10.19.22 3:21 confusion 41:12 children 33:1 crosstalk 26:6 36:6 46:6,8 47:21 connected 14:10 children's 15:8 48:14,16 54:5 current 7:14 8:25 consent 5:4 10:7 23:9 **choice** 23:16,18 committees 40:1 32:8,16,23,24 24:6 33:10 35:16, Cytotec 5:25 6:5, company 5:13 33:10,13 43:16,19 18,19 52:6,11 13 8:16 9:19,22 19:1 26:4 consequences 16:2,20 22:25 **choose** 5:5 6:11 compare 7:22 28:17 29:3,6 31:5 44:11 34:24 35:13 49:14 52:4 comparing 30:10 considerably D 27:23 chooses 23:19 complete 8:16 10:6 25:17 28:18 consideration **chose** 18:9 **D.C.** 51:9 44:3 2:9 circle 12:3 damaged 39:1 completed 28:3 considered **civil** 53:8 33:18 47:5 20:22 21:11 32:15 damages 39:5 50:2 **claim** 7:3 8:4,13 completely 43:23 damaging 39:6 constitutional 13:9 completes 29:2 **Danco** 5:13 19:1, 50:4 clarification 32:6 5,14 25:20,22,23 compliant 16:7, continue 7:24 38:24 26:2,3 36:19 20,23 clarify 15:24 contrary 47:13 Danco's 25:20 complications clarity 28:15 37:4,11,15 control 21:6 33:2, danger 29:12 8 35:1 37:6 Class 22:7 53:8 **comply** 53:12 dangerous 9:22 controlled-type 11:14 clear 35:4 39:3 conception 35:5 30:19 41:13 43:11 Daniel 23:4 concern 49:22 controversial Clemmons 4:4,6 52:16 data 13:6 19:5 32:12 17:12,14,18,22 23:3,6 37:18 concerned 50:20 18:3,7,11,15,18, **Cooper** 36:1,3,14 51:1 database 37:18 20 19:17 20:4,7, 38:2,4,6,14,21 concerns 41:19 11 21:18,20 23:24 **date** 2:8 copper 21:7 24:1,13,14 25:23, conclude 13:5 Davidson 51:8 24 26:1,5,9 40:15 correct 12:4 16:3, 40:12 41:7 49:16,17 52:12,13 4,12 17:4,10 day 27:22 concluded 54:12 29:22 43:13 **clerk** 54:10 days 27:22 conclusion 8:17 correctly 28:23 clinic 3:2.6 29:9 death 38:13 9:16.23 40:10 **country** 14:11 clinical 18:21 42:14,18 deaths 38:9 15:8 48:1 conclusions 7:5 **Debate** 47:23 **County** 51:7,8 close 22:23 8:10,12 41:1,3 **decent** 27:20 **couple** 10:19 **coast** 6:21 condition 20:24

decide 9:18 difference 35:20 equivalent 16:23 Ε decided 2:24 difficult 50:25 ER 11:22 16:9 17:1 decides 9:21 29:6 disagree 41:3 earlier 11:4 38:2 ethical 23:23 45:2 49:21 decimated 53:13 disclosure 10:6 33:12 early 11:13 14:21 decision 42:1 discover 6:3 ethics 10:4,12 51:1 easy 34:2 discovered 6:14 33:21 35:4 decisions 35:1 effect 39:8.16 evacuation 17:3 discretion 52:19 50:1,6 decrease 15:6 discussed 18:21 evaluate 12:11 effective 5:78:6 deep 22:16 19:11 22:5 evaluated 12:2, 9:25 12:22 13:9, defects 7:18 discussing 18:12 11,12 20:1 31:3 11 20:24 21:2 14:16 15:5 25:18, 31:11 48:2 50:14 **event** 37:18 discussion 2:11 21 31:14 44:23 **effects** 5:8 6:10 Disease 37:6 **events** 37:13 45:14 12:8 13:19 31:4 defer 4:8 evidence 40:11 dishonest 25:19 36:22 39:23 43:17,23 **Delgado** 6:21 8:8 exact 40:7 **Dixie** 10:16,18 31:2 11:3,19 12:3,6,20 efficacy 7:25 expect 8:11 37:21 13:13,14 15:11, delivered 6:20 embryo 5:21 9:7 expelled 5:24 12,15,20 30:4,6 7:9 13:17 14:17 36:12 39:13 31:23,25 39:18,20 24:22 44:9,15 expenditure 45:8 40:5 41:9,11 embryocidal deliveries 14:23 46:13,15,24 47:25 39:15 experience 37:10 44:17 **DNC** 9:9 experts 40:6 embryos 42:7 **delivery** 14:24,25 doctor 24:17 explain 46:15 emergency 8:19 15:3,7 45:5,6,10, 29:24 31:17 33:25 9:5,7,12,13 11:17 expulsion 5:23 34:21 37:16 democrat 51:10 extensive 2:15 doctors 22:8 emotional 50:24 10:23 demonstrate 24:4,15 37:17 emotionally extreme 51:12 7:24 doctors' 50:8 13:19 22:10 denied 53:5 extremely 35:8 dollars 45:9 encourage 51:17 deny 52:5 dose 28:24 encouraged 52:9 F **Department** 37:5 dosed 6:1 end 16:8 17:1 39:22 40:25 41:24 **facilities** 49:10,11 dozen 27:21 **ending** 50:14 deprives 39:12 **fact** 6:11 8:9 14:19 drafted 50:17 ends 35:20 depth 19:19,20 21:13 25:17 27:12 **Drafting** 3:13,14 enforcement 45:1 47:12 desired 6:17 37:8 draw 7:4 8:10,11 Faison 2:11,17, destroy 36:10 9:17 42:14.18 enormous 45:7,8 18,22 3:12,18 devastated 51:22 48:21,22 49:7 drug 5:12,13 6:18 enroll 11:11 12:1 51:3,5 developed 19:15 19:13 20:18 36:20 enrolled 11:25 37:13 **false** 22:1,10 developing 50:12 ensure 5:24 23:12 49:21 51:2, drugs 39:24 40:12 development 16 **enter** 51:14 45:13 due 41:19 familiar 39:21 environment developmental 40:2 39:4 44:23

fashion 33:12 future 24:10 33:9 healthy 14:15 18:2 **favor** 46:5 47:19 hear 22:2 34:12 indication 19:6 48:12 54:4 G heard 33:5 34:11 indications 11:14 **FDA** 18:13,14,16, 50:21 53:4 20:21,23 **gave** 6:18 10:21 22,25 19:2,4 indiscernible hearing 25:2 12:21 16:2 31:2 20:14,20 25:19 26:6 Heartbeat 4:24 general 14:25 **fees** 53:9 induced 39:24 **heavy** 9:13 generosity 43:5 felony 22:7 53:8 40:12 **high** 6:6 53:19 gentleman 51:7 female 34:11 industry 7:2,11 Hill 47:9,11 41:4,6 George 6:21 31:2 fetal 5:22 6:8 22:25 23:7,12 industry's 8:8 history 5:10 gesture 43:9 feticidal 39:15 infections 36:24 hope 22:1,10 give 2:25 3:1,17 38:10 23:12 29:7 49:21 10:5 21:24 22:1,9 fetus 39:13 51:2,16,17 49:11 51:13,15,16 inform 25:6 43:23 fields 40:8 hormone 5:17 **giving** 15:17 information 10:6 figure 9:20 29:11 32:14 43:24 48:7 **hotline** 14:7,8,18 27:4 28:5 32:14 51:2 52:11 final 24:9 30:25 25:12 27:13,21 33:17 37:10 41:17 43:15 44:3 49:11 31:16 **good** 2:18 4:16 hour 27:15 33:10 34:1,2 **informed** 5:4 10:7 **find** 8:7 14:2 hours 3:2 5:25 43:19 27:24 28:1,3 16:7 17:6 27:25 28:19,20 32:8,16,23,24 Google 14:3 findings 39:25 house 2:5,9,10, 33:10,13 41:25 graduated 17:24 finished 38:15 43:16,18 16.22 40:1 48:19 51:11 54:2 grateful 45:19 focused 8:9 informing 32:13 human 35:4,6 Grossman 23:4 focusing 41:5 initial 11:11 humane 43:9 group 11:23,24 folder 31:1 injection 31:8 12:13,17 13:7 hundreds 10:23 inside 30:1 **follow** 13:18 16:16,24 20:8 **hurdles** 53:19 44:18,19 37:20 38:19 42:4, intend 24:9 5,10 **font** 50:18 intended 39:7 I groups 16:16 **Food** 5:11 19:13 intending 53:18 31:18 20:18 36:20 37:13 **iffy** 50:16 intense 44:1 **guess** 52:16 force 53:11 immediately intent 49:20,22 **guest** 49:4 foregoing 54:11 27:11 interacted 14:18 Gynecology 8:2 forgetting 22:19 important 48:5 interest 10:9 form 21:8 incidence 37:22 Н interested 14:9 forward 12:8 included 7:14 interesting 8:7 harmful 29:2 found 6:23 27:13 increase 6:10 interfered 5:20 Harrison 6:15 15:4,5 23:12 fragile 22:10 31:13,14 42:19 interfering 39:9 **head** 19:19 **frame** 18:4 44:21 49:23 International **health** 2:5,9 15:8 free 14:5 increased 7:16 4:25 21:4 37:6 39:22 14:16 full 10:5 32:14 41:1,15,20,24 internet 27:14 43:15 independent 44:11 45:7,8

intervention 9:10 **law** 20:3,6 25:5 malpractice mic 4:14 13:7 53:13.16 51:12 52:17 53:1, Mifeprex 5:14 18 interventions mandate 40:20 12:18 25:7 26:4 12:16 laws 15:16 53:17 41:18 mifepristone intrigued 52:2 lead 36:21 mandating 22:7 5:14,21 6:4,12,17 8:15,22,24 9:18 learned 27:7 investigators manner 20:2 16:17 19:6 22:24 7:21 51:10 leave 29:9 23:7 28:17,24 involved 35:3,5 March 2:6 29:5 31:5 39:1 led 6:3 50:13 involves 13:24 maternal 15:5 legislation 25:10 Miller 34:6.8.19 **ipad** 14:3 43:20 49:20,23 matter 7:6 8:20 35:9,11,22,23 50:1,18,23 53:10 irreversible 33:3 Matthew 6:15 mind 3:4,9 5:5 liability 53:9 6:4,17 9:19 23:15, issue 23:17 32:11 meaning 8:22 19 24:22 25:7 49:21 53:3,7 life 5:22 6:8 14:20 mechanism 29:5 35:12,14 30:1 35:3,4,5,7, issues 7:19 20:3. 13:24 14:14 44:6 49:25 16,19,20 45:16 6 44:23.24 51:1 52:10 mechanisms minds 32:12 **Item** 2:16 37:8 **light** 47:12 minimum 10:1 **IUD** 21:8 medical 4:24 5:6 limited 19:22 minor 16:25 10:3 17:24 21:23 limiting 50:3 22:8 33:21 40:7 **minutes** 47:13 J 47:5 50:10 51:14 lives 38:7,9 42:22 miscarriages 52:18,22 53:11, **journal** 19:24 21:14 living 6:20 7:9 9:8 13,16 20:3,10 23:9 31:3 14:15 miscarry 17:7 medication 5:10, long 18:15 25 7:25 20:23 missed 36:7.16 Κ 21:15 26:7 27:18 longer 9:7 36:25 37:23 38:1, mom 52:11 kill 39:8 loss 5:21 6:7 11 43:16 47:6 moment 35:17 38:13 **kills** 36:11,17 medications 38:14 20:20 lost 38:7,9 41:12 kind 13:19 25:10 morning 2:18 **medicine** 4:22,23 29:24 4:16 5:1 lot 10:21 36:15 20:3,6 22:14 50:3,10,15 knowing 28:2 mother 7:17 35:7 51:20 36:18.23 Louisiana 39:22 knowledge 19:3 Meharry 4:23 40:4,25 41:24 44:8 45:20 mother's 30:2 low 22:11 23:1,7 member 4:23 **Kumar** 42:24 mothers 38:7,8,9 34:3 43:2,4,8,14 45:18 motion 2:20 3:15 members 41:23 M 46:19,22 47:16, 46:6,8 47:21 L 18,24 48:10,23 48:14,16 54:5 made 9:24 36:20 **move** 47:14 Menopausal 21:9 labor 21:15 majority 37:14 **moves** 54:7 **mention** 13:16 lack 50:10 make 4:13 8:17 Murfreesboro 12:4 28:22 35:1 mentioned 45:1 lady 2:24 51:21 4:19 41:13,17,25 52:6 method 6:9 21:6 language 47:4 makes 8:4 28:3 33:2,8 50:9,16,22 Ν **making** 35:15 methods 7:22 largest 7:13 19:25 41:17 50:24 **named** 6:15

natural 6:6 21:3 originally 20:25 **pause** 22:6 **piece** 50:18 network 27:9 outcome 42:5 **peer** 19:19,20,24 **pill** 3:1 4:25 5:6,9, 20:2 22:3 23:9 10,16 6:1 13:23 nonexistent outcomes 7:17 31:3 14:4,18 15:2 16:2, 53:19 11:13 13:6 14:13 8,11,17 17:7 27:6, 15:6 21:13 31:14 **people** 3:22 11:7 nonprofit 14:6 9,10,15 31:19,20 36:22 37:14,19, 14:2 19:15 22:16 32:25 33:14 36:9 **noted** 45:13 27:20 28:3 30:16 22,25 42:7,9,20 39:1,3,7,8 42:4,10 43:10 45:12 33:5 40:17,19 49:13 notice 50:7.16 51:24 overlooked **pills** 3:1 15:18 notify 5:3 43:21 **percent** 6:7 7:15 18:12 19:21 20:11 number 2:16 9:4 10:1,2 13:11 27:18 overwhelming 8:10,13 15:9 27:5, 15:1,3 22:5,21 22:3 44:2 20 37:12 38:17, 23:1,8,10,13 place 24:8 52:17 18,20 44:21 45:7 **oxygen** 39:13 26:17 31:13 33:7 placebo 8:22 40:18 42:21 45:5, 47:14 49:23 11:24 13:3 15:25 10,11,16 51:19,20 Ρ 16:24 31:20 numbers 8:20 52:9 **placebos** 11:6,20 nutrients 39:14 percentage 17:7 **palsy** 15:9 26:22 27:5,17 placenta 39:12 panels 40:9 **perform** 24:10,18 placental 39:11 part 16:3 27:9 performed 18:5 plan 11:11,25 **OB/GYN** 4:17 28:15 36:7,16 29:21 46:14 37:20 38:20 17:20 40:8 43:15.18 **period** 28:16 point 11:25 15:24 **OB/GYNS** 37:17 17:8 52:16 53:21 participate 18:9 perpetrator objection 4:10 51:24 points 32:18 passed 9:8 49:6 46:3 **person** 4:1,12 **pool** 22:6 Obstetrics 8:2 patient 5:4 6:3,16, 22 8:15 9:19 10:5 pertaining 2:12 pops 14:4 occur 32:24 37:21 11:15 16:6 17:5 pharmaceutical portion 16:8,9,11, 22:9,14 23:6,14, occurred 38:10 5:13 19:1 26:3 24 17:1,8 18,20,21 24:20 occurrence 35:8 25:12,15 32:9,14, **Pharmaceuticals** positions 35:21 21 43:15 occurring 24:7 19:14 36:20 positive 14:19 patient's 10:8 off-label 20:22 pharmacies 40:8 possibilities 23:18 24:6 21:16 pharmacology 43:25 patients 7:4,8,14 offices 50:8 6:2,18 possibility 3:5,7 8:5,10,13,18,21, ongoing 7:23 9:2 **Pharmacotherap** 25:14 52:10 24 9:1,4,11 10:10, **y** 19:25 24 11:1,4,9,10,16, opinion 44:3 **possibly** 51:15,16 21,22,25 12:10, phenomenon opportunity 53:5 post 49:10 12,15,25 13:2,10, 43:11 25 14:1,6,8,13,17 opposed 19:21 posted 50:8 **phone** 14:2 27:22 15:1.25 16:1.3 39:5 46:7 48:15 posting 3:7 19:23 20:1 21:24 physically 13:19 option 29:8,10 22:20 23:8 24:24 potential 5:8 25:1,9 27:8,24 physician 6:15 options 32:9 37:25 38:12 8:4 10:5 14:10 29:8 30:18,20 **oral** 31:8,9 31:4,11 41:5,8,14 17:25 23:2 34:11 potentially 35:18 42:15,19 43:10,23 47:3 **order** 5:23 practice 4:19,20 44:2 47:4 physician's 10:9 17:23 18:2 32:13, original 49:5 16 34:1

practicing 22:13 proceedings 23:17 24:19 37:16 10,17 54:11 pregnancies 9:2 providing 43:14 rates 14:24 process 5:4 7:3, 50:23 read 50:11 16 8:16 9:21 10:7 publication pregnancy 5:18, 19:18,20 20:12 reading 50:7 19,23 7:9 9:14 37:21 21:25 22:1,4 14:21 21:11,13 real 9:16 42:17 25:10,18,22 published 6:25 35:19 50:14 26:18,24 28:4,18 7:13 19:23,24 realized 51:25 32:23,24 33:11,18 pregnant 35:2 20:2 23:3,8 30:24 reason 3:3 11:15 43:20 44:10 31:2 premature 45:6 13:3 **procure** 49:13 purpose 21:1 preparation 25:2 reasons 12:23 produced 5:12 purposes 30:17 prescribe 14:11 reassurance 39:22 pursual 25:19 44:4 prescribed 21:7 produces 26:4 pursue 6:11 receive 21:10 prescription 6:19 professional 20:19 21:8 pursued 7:8 received 31:19.20 22:9 prescriptions pursuing 14:9 receiving 31:7 professional's 20:21 52:19 put 3:7 33:5 41:24 recent 8:1 50:12 presence 45:19 47:4 53:11,16,18 professionals recognized 2:17 21:24 52:22 53:12 present 36:6 10:17 13:22 17:13 Q 18:24 20:17 21:19 presentation progesterone 22:18 23:25 25:25 5:16,17,19 6:6,19 34:22 36:8,16 26:13 27:2 28:7, question 4:5 7:23 8:24 9:2 pressured 51:23, 12 29:15 30:5,14 13:15 15:13.21 11:23 12:13,18 24 32:3 33:23 34:7 21:17 24:9,19 14:21 16:1 21:3,4, 35:10 36:2 38:5 25:16 29:20 31:24 preterm 14:24,25 8,10 22:24 29:1 40:23 41:10 43:3 37:24 39:19 41:18 31:6 39:10 42:6 15:3,7 21:14 45:4, 44:13 47:10 44:7 46:2 49:4 9.17 prohibit 15:16 48:21,25 49:16 questions 3:20, 51:4 pretty 2:15 22:23 prohibits 52:17 24 4:2,8 10:15,20 50:17 53:1 recommend 4:7 26:10 28:9 43:1 21:25 23:10 prevent 21:14 45:24 54:1 promise 15:12 31:12,21 40:20 prevented 52:23 quick 10:19 **Proper** 47:16 recommendation preventing 6:7 quoted 12:21 properly 3:16 22:15 22:20 prevents 36:10 protecting 30:1 recommended previous 46:25 7:15 8:25 protocol 24:25 R recorded 54:8.9 principal 7:21 **prove** 47:6 raise 49:20 recording 2:4 principals 6:2 proven 20:23 randomized 40:16,20,21 48:2 reduce 45:9 **private** 4:20 37:17 19:10 31:7.17 provide 49:9 52:7 reduces 39:10 pro-life 23:2 rare 35:8 provided 14:6 reducing 45:17 problem 6:22 **rarity** 51:12 21:16 37:3 **provider** 23:4,21 referenced 30:6. 25:6,14 28:1 **rate** 6:7 7:7.15 9:3 18 31:22 problems 15:8 33:21 14:25 15:3 20:13 38:13 44:22 45:7 referred 25:12 22:4,6,11,16,21, providers 3:65:3 procedure 15:18 22 23:1,7,11 referring 11:8 13:25 14:10,12 49:12 31:13 42:21 45:5,

reform 53:17 24 26:1,5,9,12,14, 13:8,23 14:9,18 schedule 34:14, 21 28:6,8,13,20 15:2 16:11 17:6 15 **refuse** 23:15 29:13,14,16,23 19:16,18,20 20:13 school 4:22 17:25 refusing 10:10 30:4,6 31:23,25 24:25 26:18,23 32:4,19 33:24 27:9 30:21 31:1, science 35:3 44:8 24:5 34:6,8,19 35:9,11, 21 35:13 42:11, scientific 40:11 regard 43:20 23 36:1,3,14 38:2, 17,20 43:25 44:10 4,6,14,21 39:18, 49:13 **regimen** 5:7 7:15 **scope** 32:7,15 20 40:5,14,19 8:25 9:24 10:10 reverse 3:8,9 5:8 **scopes** 30:12 41:9,11 43:4,8,14 14:1,11 15:2 8:5 9:21 12:19 45:18 46:13,15,24 19:16,18 23:10 search 27:14 25:8 29:10 31:4 47:25 48:22 49:1, 28:25 31:1,8,11, 33:16 42:6 49:25 **seconds** 33:19 7.16.17 51:5 21 37:11,23 50:5,6 52:13 42:11,17 45:9 **sections** 10:4.11 reversed 3:5 14:4 representative's **regimens** 31:7,9 seek 27:24 24:23 28:25 39:25 5.2 40:13 44:16 47:6 regret 27:6,11,19 seeking 52:21 Representatives 33:15 53:15 reversing 7:16 35:22 25:14 regretted 28:4 self-serving 10:8 republican 51:11 review 19:19,20, released 6:25 8:1 **Senate** 51:11 **require** 5:3 10:4 24 20:2 22:4 23:5, 30:18 separate 16:15 20:19 25:5 37:1,4, 9 31:3 remind 51:8 19:21 7 47:3 49:9 rights 50:4 remorseful 44:1 series 5:9 6:24 required 9:11,14, risk 14:16 15:6 7:1,3,7 8:4,8 15 13:7 24:19 **remove** 32:13 29:8 41:15 19:12,23 20:1 42:8,11,12 43:9 removed 32:11 27:16 30:20 41:7 **room** 8:19 9:5,12, requirements 42:15 13 11:17 21:5 renew 48:22 33:13 37:16 service 14:6 **repeat** 26:20 requiring 9:9,10 rooms 47:2 session 3:25 4:3. repetitive 21:14 rescued 44:5 7,10 34:12,18 RU486 5:14 report 23:2,3 45:25 research 7:23 **Rules** 54:7 39:21,25 41:23 26:16,22 50:12 set 40:15 run 36:5 46:14 reported 6:25 residency 18:1 Shelby 51:7 7:19 30:20 37:5. respect 23:15 15,16 44:17 **Sherrell** 29:14.16. S 24:5 53:2,20 reporting 37:7,18 response 32:1 safe 5:7 6:12 8:6, **show** 31:11 42:19, reports 19:12 42:2 46:9 47:22 15 9:17,25 12:22 21 37:12 52:15 53:22 20:24 40:17 41:7 showed 7:7 Represent 52:12 responsibility safety 7:25 **shown** 4:1 6:10 43:10 representative 13:10 21:2,12 **sample** 50:11 2:11,17,18,22 responsible 45:6 26:22 45:15 3:12,18 4:4,6 sanctioned 19:4 restate 49:4 10:16,18 11:3,19 **shows** 23:6,9 save 35:7,16 12:3,6,20 13:13, 26:17 45:2 result 36:24 52:10 14 15:11,12,15,20 sic 28:11 42:24 resulted 19:2 17:12,14,18,22 saves 35:18 18:3,7,11,15,18, side 13:19 36:22 results 6:23 **saving** 14:20 20 19:17 20:4,7, 43:17 42:21 45:16 reversal 4:25 7:8 11 21:18,20 23:24 sides 50:22 53:3 8:23 9:24 10:10 24:1,13,14 25:23, **scared** 51:23

signage 46:25 sponsoring 22:4,19 23:5,8 taking 6:12 27:15 47:2 48:5 49:5,10 33:25 29:5 33:13 43:17 30:8,17,19,25 31:10,16 39:23 52:17 significant 16:9, spontaneously 40:6 42:3,18,19 10,24 17:8 45:15 9:8 talk 47:25 43.9 similar 6:22,23 **stand** 29:25 talked 27:12 50:9 subcommittee 32:23 33:12 standalone 20:15 34:11 50:22 talking 27:7 32:9 **simply** 5:3 6:5,13 standard 32:10, submitted 19:5 teaching 4:21 28:3 29:10 30:20 16 34:1,2 40:16 32:8 33:21 47:7 substantively teenager 44:16 52:20,22 22:12 simultaneous teeth 37:9 53:11, standing 52:25 26:6 **success** 5:18 6:7 15,17 standpoint 44:22 7:7,15 9:3 20:13 sincere 49:21 telling 50:9 22:4.11.16.21 stands 53:1 23:11 31:13 42:21 **single** 25:15 ten 19:9 started 24:24 successful 15:2 sir 3:12 30:3 Tennessee 2:10 30:22 state 22:10 39:25 4:22 53:14.20 situation 44:5 50:24 53:14,20 successfully tenure 50:3 **sizes** 50:11 24:23 44:16 48:2 **State's** 37:5 term 6:20 16:10, **small** 7:1.3 8:9.12 sufficient 40:11 **stated** 11:15 12,25 17:9 17:7 22:6 30:23 48:4 33:18 41:2 terms 5:15 **smart** 14:2 supplementation states 14:25 37:4, territorial 44:4 14:21 **Smith** 32:3,4,19 7,9 33:22,24 test 22:15 statistic 45:1 **supply** 39:10 so-called 52:3 tested 22:12 statistics 14:13, **support** 5:2 25:5, someday 45:3 22 10 34:23,25 35:6, testify 3:23 4:2,12 12,13,18 25:3 34:17 sought 31:18 stats 10:21 supposed 3:22 testimony 10:14 sound 12:22 **stop** 11:13 34:14 45:23 50:21 **South** 6:15 stopped 10:25 **surgery** 12:15,16 thereof 50:10 11:6 12:1,7,9,23, 13:1 37:1 42:9,11, **speak** 5:1 48:8 24 13:12 41:14,19 thing 14:4,19 12 42:3,15,16 Speaker 2:21 25:11 surgical 9:9,14 21:21 24:2 46:19, stopping 11:15 things 51:20 21 47:15 **survival** 23:1,7,12 13:4 43:8 thinking 49:24 **speaks** 42:22 survive 25:22 structured 20:2 thought 12:7 specific 27:5 studied 6:18 surviving 42:7 35:16 specifically **system** 21:9 studies 7:13 thousand 14:15. 23:20,21 39:6 10:22 13:17 22 31:10 37:19 40:24 19:12,13 30:7,11, 44:17 Т spent 47:12 50:3 16,23 31:22 36:15 thousands 10:23 44:8 50:10 **spoke** 25:1 table 47:14 tied 32:22 **study** 7:10,19,20, spoken 51:22 tabled 48:18 22 8:1,12,14,18, time 6:20 10:1,2 sponsor 47:24 21 9:17 10:25 17:8 18:4 25:6 tabling 47:18,19, 49:18 11:2,4,9,10,12,13, 28:16 33:7 41:22 24 48:10,11,12 15,24 12:9,21 44:9 45:16 49:3 sponsored 2:11 takes 9:23,24 23:6 13:4,11 15:25 50:3 53:23 16:6,25 19:22

times 28:21 44:2 two-thirds 22:16 **vote** 34:3 48:12 worried 9:5 51:21 54:9 tying 33:11 worst 43:17 tissue 5:23,24 voted 51:12 typical 11:11 wrap 43:1 9:8,15 39:11 voting 46:3 47:17 typically 3:1 wrote 23:5 today 2:15 17:16 48:10 54:2 38:11 24:16 25:2 29:19, 25 30:2,24 34:14 W 50:21 U year 5:11 37:21 told 23:22 24:3 waiting 47:2 uncertain 44:4 25:3,16,17 years 4:18,19 warning 47:4 uncommon 17:23,25 18:1 toll-free 14:7 Washington 51:9 43:11 19:5,8 21:5 22:13 tort 53:17 27:8 51:9 understand 52:5 website 13:24 total 11:22 50:19 yesterday 25:2 understood track 44:21 28:22 week 27:22 34:10, young 2:24 51:21 15 tracked 14:14 undertaken 40:4 weeks 19:8,9 trained 18:8 undo 52:1 24:25 27:13 21:23 undue 33:19 west 6:21 training 18:10 unfavorable 7:17 White 28:11,13,20 transcribed 2:4 UNIDENTIFIED 29:13 48:24 49:1, transfusion 9:11, 2:21 46:19,21 8 15 12:14,17 13:1 47:15 **widely** 21:13 37:1 42:8,13 **United 14:25** wished 31:4 transfusions universal 25:11 17:2 woman 29:2,4 31:15 33:20 35:12 University 4:22 treated 8:23 53:4 unstable 39:12 treating 10:5 32:7 woman's 33:11 **unusual** 36:24 treatment 5:11 34:23,25 6:9 9:12 12:25 **uterus** 39:11 **womb** 30:2 13:2,8,9 22:22 43:24 51:14 women 6:11 21:5. V 9 22:1 26:17,23 trial 18:25 19:2,10 27:5,10,18 29:12 41:20 variety 31:6 31:18 36:23,25 trials 18:21,22 37:10,25 41:15,20 vast 35:20 37:14 19:4,11 47:5 48:1, 42:3,5,20 44:18 verbal 49:11 48:3 49:12,24 50:4,23 trimester 5:20 verbiage 47:8 48:4 women's 21:4 truth 7:6 8:19 52:4 versus 31:8 truthfully 24:20 words 36:11 viewed 32:8 **tubes** 32:22 33:5, work 22:2 33:16 11 vigorously 41:3 51:15 twelve 8:18 11:7, violation 10:11 working 38:19,20 10,17,21,25 12:2, virtually 53:18 10 works 33:6 vital 5:17

Υ